985 related articles for article (PubMed ID: 10431024)
1. Impact of immunosuppression and acute rejection on recurrence of hepatitis C: results of the National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database.
Charlton M; Seaberg E
Liver Transpl Surg; 1999 Jul; 5(4 Suppl 1):S107-14. PubMed ID: 10431024
[TBL] [Abstract][Full Text] [Related]
2. Predictors of patient and graft survival following liver transplantation for hepatitis C.
Charlton M; Seaberg E; Wiesner R; Everhart J; Zetterman R; Lake J; Detre K; Hoofnagle J
Hepatology; 1998 Sep; 28(3):823-30. PubMed ID: 9731579
[TBL] [Abstract][Full Text] [Related]
3. Use of OKT3 is associated with early and severe recurrence of hepatitis C after liver transplantation.
Rosen HR; Shackleton CR; Higa L; Gralnek IM; Farmer DA; McDiarmid SV; Holt C; Lewin KJ; Busuttil RW; Martin P
Am J Gastroenterol; 1997 Sep; 92(9):1453-7. PubMed ID: 9317061
[TBL] [Abstract][Full Text] [Related]
4. Hepatitis C etiology of liver disease is strongly associated with early acute rejection following liver transplantation.
McTaggart RA; Terrault NA; Vardanian AJ; Bostrom A; Feng S
Liver Transpl; 2004 Aug; 10(8):975-85. PubMed ID: 15390322
[TBL] [Abstract][Full Text] [Related]
5. Survival and hepatitis C virus recurrence after liver transplantation in HIV- and hepatitis C virus-coinfected patients: experience in a single center.
Testillano M; Fernandez JR; Suarez MJ; Gastaca M; Bustamante J; Pijoan JI; Montejo M; Valdivieso A; Ruiz P; Gonzalez J; Ortiz de Urbina J
Transplant Proc; 2009 Apr; 41(3):1041-3. PubMed ID: 19376421
[TBL] [Abstract][Full Text] [Related]
6. Impact of sirolimus and tacrolimus on mortality and graft loss in liver transplant recipients with or without hepatitis C virus: an analysis of the Scientific Registry of Transplant Recipients Database.
Watt KD; Dierkhising R; Heimbach JK; Charlton MR
Liver Transpl; 2012 Sep; 18(9):1029-36. PubMed ID: 22641474
[TBL] [Abstract][Full Text] [Related]
7. Steroid-free living donor liver transplantation in adults: impact on hepatitis C recurrence.
Marubashi S; Dono K; Nagano H; Kim C; Asaoka T; Hama N; Kobayashi S; Takeda Y; Umeshita K; Monden M; Doki Y; Mori M
Clin Transplant; 2009; 23(6):904-13. PubMed ID: 19573088
[TBL] [Abstract][Full Text] [Related]
8. Factors influencing renal function after liver transplantation. Results from the MOST, an international observational study.
Burra P; Senzolo M; Masier A; Prestele H; Jones R; Samuel D; Villamil F
Dig Liver Dis; 2009 May; 41(5):350-6. PubMed ID: 19046932
[TBL] [Abstract][Full Text] [Related]
9. Repeated steroid pulse therapies in HCV-positive liver recipients: significant risk factor for HCV-related graft loss.
Bahra M; Neumann UP; Jacob D; Langrehr JM; Neuhaus P
Transplant Proc; 2005 May; 37(4):1700-2. PubMed ID: 15919436
[TBL] [Abstract][Full Text] [Related]
10. Differential allograft gene expression in acute cellular rejection and recurrence of hepatitis C after liver transplantation.
Sreekumar R; Rasmussen DL; Wiesner RH; Charlton MR
Liver Transpl; 2002 Sep; 8(9):814-21. PubMed ID: 12200784
[TBL] [Abstract][Full Text] [Related]
11. Histological and clinical outcome after liver transplantation for hepatitis C.
Shuhart MC; Bronner MP; Gretch DR; Thomassen LV; Wartelle CF; Tateyama H; Emerson SS; Perkins JD; Carithers RL
Hepatology; 1997 Dec; 26(6):1646-52. PubMed ID: 9398011
[TBL] [Abstract][Full Text] [Related]
12. Impact of hepatitis C infection on outcomes after heart transplantation.
Fong TL; Hou L; Hutchinson IV; Cicciarelli JC; Cho YW
Transplantation; 2009 Nov; 88(9):1137-41. PubMed ID: 19898211
[TBL] [Abstract][Full Text] [Related]
13. Management of recurrence of hepatitis C infection following liver transplantation.
Charlton M
Minerva Chir; 2003 Oct; 58(5):717-24. PubMed ID: 14603150
[TBL] [Abstract][Full Text] [Related]
14. Recurrent hepatitis C posttransplant: early preservation injury may predict poor outcome.
Watt KD; Lyden ER; Gulizia JM; McCashland TM
Liver Transpl; 2006 Jan; 12(1):134-9. PubMed ID: 16382465
[TBL] [Abstract][Full Text] [Related]
15. Fibrosing cholestatic hepatitis in renal transplant recipients with hepatitis C virus infection.
Delladetsima JK; Boletis JN; Makris F; Psichogiou M; Kostakis A; Hatzakis A
Liver Transpl Surg; 1999 Jul; 5(4):294-300. PubMed ID: 10388502
[TBL] [Abstract][Full Text] [Related]
16. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients.
Berenguer M; Prieto M; San Juan F; Rayón JM; Martinez F; Carrasco D; Moya A; Orbis F; Mir J; Berenguer J
Hepatology; 2002 Jul; 36(1):202-10. PubMed ID: 12085366
[TBL] [Abstract][Full Text] [Related]
17. [Treatment of recurrent HCV infection after liver transplantation].
Ostojić R
Acta Med Croatica; 2005; 59(5):443-6. PubMed ID: 16381241
[TBL] [Abstract][Full Text] [Related]
18. The Tor Vergata weaning off immunosuppression protocol in stable HCV liver transplant patients: the updated follow up at 78 months.
Orlando G; Manzia T; Baiocchi L; Sanchez-Fueyo A; Angelico M; Tisone G
Transpl Immunol; 2008 Nov; 20(1-2):43-7. PubMed ID: 18773958
[TBL] [Abstract][Full Text] [Related]
19. Impact of immunosuppression on immunopathogenesis of liver damage in hepatitis C virus-infected recipients following liver transplantation.
McCaughan GW; Zekry A
Liver Transpl; 2003 Nov; 9(11):S21-7. PubMed ID: 14586891
[TBL] [Abstract][Full Text] [Related]
20. Long-term results and modeling to predict outcomes in recipients with HCV infection: results of the NIDDK liver transplantation database.
Charlton M; Ruppert K; Belle SH; Bass N; Schafer D; Wiesner RH; Detre K; Wei Y; Everhart J
Liver Transpl; 2004 Sep; 10(9):1120-30. PubMed ID: 15350002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
